Deal-Making, Financing Coalesce Around Promising CAR-T Space In Cancer
Executive Summary
A huge IPO for Kite Pharma and two massive venture rounds for Juno Therapeutics have those two newer companies out in front in CAR therapeutics, but bigger, more established firms like Novartis, Pfizer and Celgene are in the game, while other companies, like biotech Bellicum, are looking to get in. Can Kite and Juno stay ahead and stand alone?
You may also be interested in...
Gene Editing: Rewriting The Code
Gene editing technologies, which enable knockout or modification of specific genes, could get first use in modifying T cells to fight cancer and HIV, but its long-term potential to control gene expression in vivo has sparked Series A financings of three start-ups in the past 18 months.
Acute Lymphoblastic Leukemia Poised To Be First, Fast Driver Of CAR Immunotherapy
Given high complete response rates in early studies showcased at the American Society of Hematology’s recent annual meeting, acute lymphoblastic leukemia is a likely launch indication for chimeric antigen receptor immunotherapy. But while the results in B-cell malignancies are very promising so far, autologous CAR therapies are complex, and toxicities need to be carefully managed.
Juno Therapeutics Enters Battle Over CAR Cancer Immunotherapy Technology
University of Pennsylvania seeks court order that its cancer immunotherapy does not infringe St. Jude’s patent; Juno, which licensed the patent for the potential leukemia treatment, has joined the settlement talks.